Allergic Conjunctivitis Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Report Summary

GlobalData's report, “Allergic Conjunctivitis Therapeutics - Pipeline Assessment and Market Forecasts to 2018”, is an essential source of information and analysis on the global allergic conjunctivitis therapeutics market. The report identifies the key trends shaping and driving the global market. The report also provides insights into the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global allergic conjunctivitis therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates that the global allergic conjunctivitis therapeutics market was valued at $970m in 2010, which is expected to grow at a Compound Annual Growth Rate (CAGR) of 14.3% over the next eight years, to reach $2.8bn by 2018. The increase in disease awareness is expected to lead to a growth in the diagnosed and treated population which will be further complemented by rising compliance due to the availability of a sufficient number of treatment options including branded, generics and OTC (Over the Counter) products. The increase in the treated patient population, the increasing uptake of medications and the rising compliance will be the primary drivers for the growth of the allergic conjunctivitis therapeutics market in the future. There are no major pipeline products which are expected to drive the market. The major late stage products in the allergic conjunctivitis therapeutics pipeline are modified pollen extracts which cater to a niche population only.

Scope

The report provides information on the key drivers and challenges of the Allergic Conjunctivitis Therapeutics market. Its scope includes -

• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Allergic Conjunctivitis Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
• Analysis of the current and future competition in the seven key countries Allergic Conjunctivitis Therapeutics market.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Allergic Conjunctivitis Therapeutics market.
• Analysis of key recent licensing and partnership agreements in Allergic Conjunctivitis Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global Allergic Conjunctivitis Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Allergic Conjunctivitis Therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global Allergic Conjunctivitis Therapeutics market landscape? - Identify, understand and capitalize.

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Allergic Conjunctivitis Therapeutics: Introduction
2.1 Disease Overview
2.1.1 Intermittent or Seasonal Allergic Conjunctivitis (SAC)
2.1.2 Persistent or Perennial Allergic Conjunctivitis (PAC)
2.1.3 Vernal Keratoconjunctivitis (VKC)
2.1.4 Atopic Keratoconjunctivitis (AKC)
2.1.5 Giant Papillary Conjunctivitis (GPC)
2.2 Epidemiology
2.3 Etiology and Pathology
2.4 Signs and Symptoms
2.5 Diagnosis
2.6 Treatment and Management Pattern
2.6.1 Non-Pharmacological Intervention
2.6.2 Pharmacological Interventions
2.7 Referral Pathway
2.8 GlobalData Pipeline Report Guidance

3 Allergic Conjunctivitis Therapeutics: Market Characterization
3.1 Allergic Conjunctivitis Therapeutics Market Size (2005-2010) - Global
3.2 Allergic Conjunctivitis Therapeutics Market Forecast (2010-2018) - Global
3.3 Allergic Conjunctivitis Therapeutics Market Size (2005-2010) - The US
3.4 Allergic Conjunctivitis Therapeutics Market Forecast (2010-2018) - The US
3.5 Allergic Conjunctivitis Therapeutics Market Size (2005-2010) - France
3.6 Allergic Conjunctivitis Therapeutics Market Forecast (2010-2018) - France
3.7 Allergic Conjunctivitis Therapeutics Market Size (2005-2010) - Germany
3.8 Allergic Conjunctivitis Therapeutics Market Forecast (2010-2018) - Germany
3.9 Allergic Conjunctivitis Therapeutics Market Size (2005-2010) - Italy
3.10 Allergic Conjunctivitis Therapeutics Market Forecast (2010-2018) - Italy
3.11 Allergic Conjunctivitis Therapeutics Market Size (2005-2010) - Spain
3.12 Allergic Conjunctivitis Therapeutics Market Forecast (2010-2018) - Spain
3.13 Allergic Conjunctivitis Therapeutics Market Size (2005-2010) - The UK
3.14 Allergic Conjunctivitis Therapeutics Market Forecast (2010-2018) - The UK
3.15 Allergic Conjunctivitis Therapeutics Market Size (2005-2010) - Japan
3.16 Allergic Conjunctivitis Therapeutics Market Forecast (2010-2018) - Japan
3.17 Drivers and Barriers for the Allergic Conjunctivitis therapeutics market
3.17.1 Drivers for the Allergic Conjunctivitis therapeutics market
3.17.2 Barriers for the Allergic Conjunctivitis therapeutics market
3.17.3 Opportunity and Unmet need analysis
3.18 Key Takeaway

4 Allergic Conjunctivitis Therapeutics: Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles for the Major Marketed Products in the Allergic Conjunctivitis Therapeutics Market
4.3.1 Pataday (olopatadine hydrochloride ophthalmic solution) 0.2%
4.3.2 Patanol/Opatanol (olopatadine hydrochloride ophthalmic solution) 0.1%
4.3.3 Elestat (0.05% epinastine HCl ophthalmic solution)
4.3.4 Alomide (0.1% lodoxamide tromethamine ophthalmic solution)
4.3.5 Bepreve (1.5% bepotastine besilate ophthalmic solution)
4.3.6 Optivar (azelastine hydrochloride)
4.3.7 Lastacaft (alcaftadine ophthalmic solution)
4.4 Key Takeaway

5 Allergic Conjunctivitis Therapeutics: Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Allergic Conjunctivitis Therapeutics Pipeline - Pipeline by Phase of Development
5.3.1 Allergic Conjunctivitis Therapeutics - Phase III Pipeline
5.3.2 Allergic Conjunctivitis Therapeutics - Phase II Pipeline
5.3.3 Allergic Conjunctivitis Therapeutics - Discovery and Pre-Clinical Pipeline
5.3.4 Technology Trends Analytic Framework
5.4 Allergic Conjunctivitis Therapeutics Market -Pipeline by Mechanism of Action
5.5 Allergic Conjunctivitis Therapeutics - Promising Drugs under Clinical Development
5.6 Molecule Profile for Promising Drugs under Clinical Development
5.6.1 SCH 697243/ Grass Sublingual Tablet
5.6.2 SCH 039641 / Ragweed Sublingual Tablet
5.6.3 AC-170
5.6.4 DE-114 ophthalmic solution
5.7 Key Takeaway

6 Allergic Conjunctivitis Therapeutics: Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Companies Participating in Allergic Conjunctivitis Therapeutics Clinical Trials

7 Strategic Assessment
7.1 Key Events Impacting on the Future Market
7.2 Allergic Conjunctivitis Therapeutics: Implications for Future Market Competition

8 Allergic Conjunctivitis Therapeutics: Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Merck & Co., Inc.
8.2.2 Aciex Therapeutics, Inc.
8.2.3 Santen Pharmaceutical Co., Ltd.
8.2.4 Other Companies in the Allergic Conjunctivitis Therapeutics Market

9 Allergic Conjunctivitis Therapeutics: Licensing and Partnership Deals

10 Allergic Conjunctivitis Therapeutics: Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

List of Tables

Table 1: Prevalence of Allergic Conjunctivitis by Country (G7)
Table 2: Allergic Conjunctivitis- Etiology
Table 3: Classification of Antiallergic Medications
Table 4: Allergic Conjunctivitis Therapeutics Market, Global, Revenue ($m), 2005-2010
Table 5: Allergic Conjunctivitis Therapeutics Market, Global, Forecast ($m), 2010-2018
Table 6: Allergic Conjunctivitis Therapeutics Market, the US, Revenue ($m), 2005-2010
Table 7: Allergic Conjunctivitis Therapeutics Market, the US, Forecasts ($m), 2010-2018
Table 8: Allergic Conjunctivitis Therapeutics Market, France, Revenue ($m), 2005-2010
Table 9: Allergic Conjunctivitis Therapeutics Market, France, Forecasts ($m), 2010-2018
Table 10: Allergic Conjunctivitis Therapeutics Market, Germany, Revenue ($m), 2005-2010
Table 11: Allergic Conjunctivitis Therapeutics Market, Germany, Forecasts ($m), 2010-2018
Table 12: Allergic Conjunctivitis Therapeutics Market, Italy, Revenue ($m), 2005-2010
Table 13: Allergic Conjunctivitis Therapeutics Market, Italy, Forecasts ($m), 2010-2018
Table 14: Allergic Conjunctivitis Therapeutics Market, Spain, Revenue ($m), 2005-2010
Table 15: Allergic Conjunctivitis Therapeutics Market, Spain, Forecasts ($m), 2010-2018
Table 16: Allergic Conjunctivitis Therapeutics Market, the UK, Revenue ($m), 2005-2010
Table 17: Allergic Conjunctivitis Therapeutics Market, the UK, Forecasts ($m), 2010-2018
Table 18: Allergic Conjunctivitis Therapeutics Market, Japan, Revenue ($m), 2005-2010
Table 19: Allergic Conjunctivitis Therapeutics Market, Japan, Forecasts ($m), 2010-2018
Table 20: Clinical study details
Table 21: Clinical study details
Table 22: Allergic Conjunctivitis Therapeutics, Phase III Pipeline, 2011
Table 23: Allergic Conjunctivitis Therapeutics, Phase II Pipeline, 2011
Table 24: Allergic Conjunctivitis Therapeutics, Preclinical Pipeline, 2011
Table 25: Allergic Conjunctivitis Therapeutics - Most Promising Drugs under Clinical Development, 2011
Table 26: Allergic Conjunctivitis Therapeutics, Clinical Trials by Country, 2011
Table 27: Allergic Conjunctivitis Therapeutics - Clinical Trials by Phase, 2011
Table 28: Allergic Conjunctivitis Therapeutics, Clinical Trials by Status, 2011
Table 29: Allergic Conjunctivitis Therapeutics, Prominent Sponsors, 2011
Table 30: Allergic Conjunctivitis Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011
Table 31: Merck & Co., Inc., Allergic Conjunctivitis Management, Pipeline, 2011
Table 32: Merck & Co., Inc., Ophthalmology, Pipeline, 2011
Table 33: Aciex Therapeutics, Inc., Allergic Conjunctivitis, Pipeline, 2011
Table 34: Santen Pharmaceutical Co., Ltd. - Allergic Conjunctivitis Management, Pipeline, 2011
Table 35: Santen Pharmaceutical Co., Ltd. - Ophthalmology, Pipeline, 2011
Table 36: Allergic Conjunctivitis Therapeutics Market, Future Players
Table 37: Allergic Conjunctivitis Therapeutics, Global, Deals, 2009-2011

List of Figures

Figure 1: Pathophysiology of Allergic Conjunctivitis
Figure 2: Diagnostic Techniques
Figure 3: Referral Pathway
Figure 4: Allergic Conjunctivitis Therapeutics Market, Global, Revenue ($m), 2005-2010
Figure 5: Allergic Conjunctivitis Therapeutics Market, Global, Forecast ($m), 2010-2018
Figure 6: Allergic Conjunctivitis Therapeutics Market, the US, Forecast ($m), 2005-2010
Figure 7: Allergic Conjunctivitis Therapeutics Market, the US, Forecast ($m), 2010-2018
Figure 8: Allergic Conjunctivitis Therapeutics Market, France, Revenue ($m), 2005-2010
Figure 9: Allergic Conjunctivitis Therapeutics Market, France, Forecast ($m), 2010-2018
Figure 10: Allergic Conjunctivitis Therapeutics Market, Germany, Revenue ($m), 2005-2010
Figure 11: Allergic Conjunctivitis Therapeutics Market, Germany, Forecast ($m), 2010-2018
Figure 12: Allergic Conjunctivitis Therapeutics Market, Italy, Revenue ($m), 2005-2010
Figure 13: Allergic Conjunctivitis Therapeutics Market, Italy, Forecast ($m), 2010-2018
Figure 14: Allergic Conjunctivitis Therapeutics Market, Spain, Revenue ($m), 2005-2010
Figure 15: Allergic Conjunctivitis Therapeutics Market, Spain, Forecast ($m), 2010-2018
Figure 16: Allergic Conjunctivitis Therapeutics Market, the UK, Revenue ($m), 2005-2010
Figure 17: Allergic Conjunctivitis Therapeutics Market, the UK, Forecast ($m), 2010-2018
Figure 18: Allergic Conjunctivitis Therapeutics Market, Japan, Revenue ($m), 2005-2010
Figure 19: Allergic Conjunctivitis Therapeutics Market, Japan, Forecast ($m), 2010-2018
Figure 20: Opportunity and Unmet Need in the Allergic Conjunctivitis Therapeutics Market, 2011
Figure 21: Allergic Conjunctivitis Therapeutics, Strategic Competitor Assessment, 2010
Figure 22: Allergic Conjunctivitis Therapeutics - Pipeline by Phase of Development, 2011
Figure 23: Allergic Conjunctivitis Therapeutics, Technology Trends Analytics Framework, 2011
Figure 24: Allergic Conjunctivitis Pipeline, Technology Trends Analytics Framework, Description, 2011
Figure 25: Allergic Conjunctivitis Therapeutics, Pipeline by Mechanism of Action, 2011
Figure 26: Allergic Conjunctivitis Therapeutics, Clinical Trials by Country, 2011
Figure 27: Allergic Conjunctivitis Therapeutics, Clinical Trials by Phase (%), 2011
Figure 28: Allergic Conjunctivitis Therapeutics, Clinical Trials by Status (%), 2011
Figure 29: Allergic Conjunctivitis Therapeutics, Overall Sponsors (%), 2011
Figure 30: Allergic Conjunctivitis Therapeutics, Prominent Sponsors (%), 2011
Figure 31: Allergic Conjunctivitis Therapeutics Market, Drivers and Restraints, 2011
Figure 32: Implications for Future Market Competition in the Allergic Conjunctivitis Therapeutics , 2011
Figure 33: Allergic Conjunctivitis Therapeutics Market, Pipeline by Company, 2011
Figure 34: GlobalData Market Forecasting Model